A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer.

And then, among the 93 patients who had not received chemotherapy, those with favorable-phenotype tumors had significantly or almost significantly longer DFS than those with unfavorable-phenotype tumors ( P = 0.0002).

also in 555 other papers